Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ENLV.TA
- Price
- 2.70
- Stock movement up
- +0.01 (0.26%)
- Company name
- Enlivex Therapeutics Ltd
- Exchange
- (TA ,
- Currency
- ILA )
- Sector
- Healthcare >Biotechnology
- Market cap
- 638.46M
- Ent value
- 637.84M
- Price/Sales
- -
- Price/Book
- 36.52
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -6.91%
- 1 year return
- -37.63%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-17
DIVIDENDS
ENLV.TA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 36.52 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 236.29M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.08M |
| Net receivables | 0.00 |
| Total current assets | 19.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.78M |
| Total assets | 20.94M |
| Accounts payable | 375.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 3.03M |
| Total liabilities | 3.46M |
| Shareholder's equity | 17.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.69 |
| Daily high | 2.83 |
| Daily low | 2.65 |
| Daily Volume | 165K |
| All-time high | 14150.00 |
| 1y analyst estimate | - |
| Beta | 1.48 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ENLV.TA | S&P500 | |
| Current price drop from All-time high | -99.98% | -2.58% |
| Highest price drop | -99.98% | -19.00% |
| Date of highest drop | 16 Dec 2025 | 8 Apr 2025 |
| Avg drop from high | -97.61% | -2.63% |
| Avg time to new high | - | 6 days |
| Max time to new high | 299 days | 89 days |
COMPANY DETAILS
Marketcap
638.46M
Marketcap category
Small-cap
Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Israel
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Biopharma firm sets its sights on Rain Protocol’s native token. Rain is an Arbitrum-based prediction market protocol. Prediction markets tipped to reach $96 billion in 10 years.
November 25, 2025
Nasdaq-listed Enlivex Therapeutics has unveiled plans to raise about $212 million in a private placement to build a Rain token-focused digital asset treasury, positioning the project as the first pred...
November 24, 2025
Enlivex Therapeutics is raising $212 million to invest in RAIN, the token of a blockchain-based prediction market, which will become its main treasury reserve asset.
November 24, 2025
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) on Monday announced a private investment in public equity of 212 million shares at $1.00 per share, representing a premium of 11.5% from the closing price of th...
November 24, 2025
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive...
November 24, 2025
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it ...
October 28, 2025
ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small St...
October 3, 2025
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a li...
September 29, 2025
ORLANDO, FLORIDA / ACCESS Newswire / September 19, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the R...
September 19, 2025
Next page